Recent advances in the diagnosis and management of cryptococcal meningitis are
promising and have been improving long-term survival. Point of care testing has made …

A small group of clinical researchers, of whom I was one, recently traveled to Thailand to
initiate a collaborative, randomized, prospective study on the treatment of acute cryptococcal …

Abstract Treatment guidelines recommend combination antifungal therapy with amphotericin
B (AmB) as an induction therapy for cryptococcal meningitis. The objective of this study was …

Cryptococcal meningitis (CM) remains a major cause of morbidity and mortality among
immunocompromised patients, especially in areas of high HIV prevalence, although it can …

Six years after the first Society guidelines were published, cryptococcal meningitis (CM)
remains an important cause of morbidity and mortality among HIV-infected adults in South …

Abstract (See the Editorial Commentary by Bennett, on pages 129–30.) Background. HIV-
associated cryptococcal meningitis is associated with an estimated 600 000 deaths …

Background Cryptococcal meningitis accounts for more than 100,000 human
immunodeficiency virus (HIV)–related deaths per year. We tested two treatment strategies …

Background Treatment with low-dose amphotericin B (0.4 mg per kilogram of body weight
per day) or oral azole therapy in patients with the acquired immunodeficiency syndrome …

Cryptococcal meningitis remains a substantial health burden with high morbidity, particularly
in developing countries. Antifungal treatment regimens are guided by host factors, severity of …

Cryptococcal meningoencephalitis was first described over a century ago. This fungal
infection is preventable and treatable yet continues to be associated with excessive …